These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 10632339)

  • 61. Estrogen and progesterone receptor status as prognostic indicators in patients with optimally cytoreduced stage IIIc serous cystadenocarcinoma of the ovary.
    Geisler JP; Wiemann MC; Miller GA; Geisler HE
    Gynecol Oncol; 1996 Mar; 60(3):424-7. PubMed ID: 8774651
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Prognostic significance of p53 expression in ovarian granulosa cell tumors.
    Ala-Fossi SL; Mäenpää J; Aine R; Koivisto P; Koivisto AM; Punnonen R
    Gynecol Oncol; 1997 Sep; 66(3):475-9. PubMed ID: 9299263
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Immunohistochemical analysis of drug resistance-associated proteins in ovarian carcinomas.
    Mayr D; Pannekamp U; Baretton GB; Gropp M; Meier W; Flens MJ; Scheper R; Diebold J
    Pathol Res Pract; 2000; 196(7):469-75. PubMed ID: 10926324
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Estrogen receptor expression is a common feature of ovarian borderline tumors.
    Abu-Jawdeh GM; Jacobs TW; Niloff J; Cannistra SA
    Gynecol Oncol; 1996 Feb; 60(2):301-7. PubMed ID: 8631556
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Prognostic significance of p53 overexpression in endometrial cancer.
    Ito K; Watanabe K; Nasim S; Sasano H; Sato S; Yajima A; Silverberg SG; Garrett CT
    Cancer Res; 1994 Sep; 54(17):4667-70. PubMed ID: 8062261
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Prognostic factors and survival of borderline ovarian tumors in Rajavithi Hospital between 1979-2006 A.D.
    Sornsukolrat S; Tuipae S
    J Med Assoc Thai; 2012 Sep; 95(9):1141-8. PubMed ID: 23140030
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Survival in patients with clear cell carcinoma of the ovary].
    Nakano T; Enoki K; Nakashima M; Ishikawa H; Ametani Y; Ohta S; Ohkuchi A; Satake S; Kojima Y; Funamoto H; Tateno M; Miwa A
    Gan To Kagaku Ryoho; 1998 Jan; 25(1):67-73. PubMed ID: 9464331
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Mutation and overexpression of p53 in early-stage epithelial ovarian cancer.
    Kohler MF; Kerns BJ; Humphrey PA; Marks JR; Bast RC; Berchuck A
    Obstet Gynecol; 1993 May; 81(5 ( Pt 1)):643-50. PubMed ID: 8469448
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Epithelial ovarian tumors of borderline malignancy: long-term follow-up.
    Casey AC; Bell DA; Lage JM; Fuller AF; Nikrui N; Rice LW
    Gynecol Oncol; 1993 Sep; 50(3):316-22. PubMed ID: 8406194
    [TBL] [Abstract][Full Text] [Related]  

  • 70. p53 protein overexpression in early stage endometrial cancer.
    Kohlberger P; Gitsch G; Loesch A; Tempfer C; Kaider A; Reinthaller A; Kainz C; Breitenecker G
    Gynecol Oncol; 1996 Aug; 62(2):213-7. PubMed ID: 8751552
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Excision repair cross-complementation group 1 protein overexpression as a predictor of poor survival for high-grade serous ovarian adenocarcinoma.
    Scheil-Bertram S; Tylus-Schaaf P; du Bois A; Harter P; Oppitz M; Ewald-Riegler N; Fisseler-Eckhoff A
    Gynecol Oncol; 2010 Nov; 119(2):325-31. PubMed ID: 20728204
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Prognostic value of lymph node involvement in ovarian serous borderline tumors.
    Lesieur B; Kane A; Duvillard P; Gouy S; Pautier P; Lhommé C; Morice P; Uzan C
    Am J Obstet Gynecol; 2011 May; 204(5):438.e1-7. PubMed ID: 21349494
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Expression of glucose transporter protein 1 and p63 in serous ovarian tumor.
    Cai Y; Zhai JJ; Feng BB; Duan XZ; He XJ
    J Obstet Gynaecol Res; 2014 Jul; 40(7):1925-30. PubMed ID: 25056472
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Prognostic significance of fascin expression in advanced poorly differentiated serous ovarian cancer.
    Daponte A; Kostopoulou E; Papandreou CN; Daliani DD; Minas M; Koukoulis G; Messinis IE
    Anticancer Res; 2008; 28(3B):1905-10. PubMed ID: 18630479
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Long-term follow-up of borderline ovarian tumors clinical outcome and prognostic factors.
    Lazarou A; Fotopoulou C; Coumbos A; Sehouli J; Vasiljeva J; Braicu I; Burger H; Kuehn W
    Anticancer Res; 2014 Nov; 34(11):6725-30. PubMed ID: 25368281
    [TBL] [Abstract][Full Text] [Related]  

  • 76. p53 signature and serous tubal in-situ carcinoma in cases of primary tubal and peritoneal carcinomas and serous borderline tumors of the ovary.
    Leonhardt K; Einenkel J; Sohr S; Engeland K; Horn LC
    Int J Gynecol Pathol; 2011 Sep; 30(5):417-24. PubMed ID: 21804388
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Ovarian serous borderline tumor: the prognostic relation to the pathologic features and management].
    Zhou XR; Du XG
    Zhonghua Fu Chan Ke Za Zhi; 1994 Oct; 29(10):601-3, 637. PubMed ID: 7712874
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Clinicopathologic analysis of low-stage sporadic ovarian carcinomas: a reappraisal.
    Karamurzin Y; Leitao MM; Soslow RA
    Am J Surg Pathol; 2013 Mar; 37(3):356-67. PubMed ID: 23282975
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Long-term Behavior of Serous Borderline Tumors Subdivided Into Atypical Proliferative Tumors and Noninvasive Low-grade Carcinomas: A Population-based Clinicopathologic Study of 942 Cases.
    Vang R; Hannibal CG; Junge J; Frederiksen K; Kjaer SK; Kurman RJ
    Am J Surg Pathol; 2017 Jun; 41(6):725-737. PubMed ID: 28248817
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Prognosis and management of borderline tumours of the ovary.
    Tropé C; Kaern J
    Curr Opin Obstet Gynecol; 1996 Feb; 8(1):12-6. PubMed ID: 8777251
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.